Oxford, UK, November 22, 2022 (Yahoo) -- Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces the appointment of Dr Frank Mathias as Chief Executive Officer (CEO) and Board Director, effective March 2023.
Read full article here.
San Diego, CA, April 3, 2024 (Reuters) -- Alterome Therapeutics announced that it has successfully secured $132 million. Spearheaded by Goldman Sachs Alternatives, this a series B financing brings f
Henderson, NV, April 8, 2024 (Zura Bio) -- Zura Bio, a company focused on advancing treatments for autoimmune and inflammatory conditions, has named Robert Lisicki as its new Chief Executive Officer
Cambridge, MA, April 3, 2024 (Business Wire) -- Obsidian Therapeutics, Inc., a cutting-edge clinical-stage biotechnology company specializing in engineered cell and gene therapies, recently conclude
